E Premkumar Reddy

List of Publications by Year
in descending order

33 papers	1,708 citations	623734 14 h-index	501196 28 g-index
34 all docs	34 docs citations	34 times ranked	3785 citing authors

#	Article	IF	Citations
1	Drugging the 'undruggable' cancer targets. Nature Reviews Cancer, 2017, 17, 502-508.	28.4	620
2	JNK-signaling: A multiplexing hub in programmed cell death. Genes and Cancer, 2017, 8, 682-694.	1.9	271
3	A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling. Cell, 2016, 165, 643-655.	28.9	228
4	Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia. Cell Stem Cell, 2017, 20, 315-328.e7.	11.1	114
5	The Ins and Outs of Bcr-Abl Inhibition. Genes and Cancer, 2012, 3, 447-454.	1.9	93
6	Discovery of a Clinical Stage Multi-Kinase Inhibitor Sodium (E)-2-{2-Methoxy-5-[(2â€²,4â€²,6â€²-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): Synthesis, Structureâ€“Activity Relationship, and Biological Activity. Journal of Medicinal Chemistry, 2011, 54, 6254-6276.	6.4	84
7	Angiomotin stabilization by tankyrase inhibitors antagonizes constitutive TEAD-dependent transcription and proliferation of human tumor cells with Hippo pathway core component mutations. Oncotarget, 2016, 7, 28765-28782.	1.8	43
8	A Role for the Epidermal Growth Factor Receptor Signaling in Development of Intestinal Serrated Polyps in Mice and Humans. Gastroenterology, 2012, 143, 730-740.	1.3	32
9	Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease. Nature Communications, 2021, 12, 4671.	12.8	28
10	Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma. Cancer Research, 2016, 76, 1225-1236.	0.9	25
11	Rigosertib Is a More Effective Radiosensitizer Than Cisplatin in Concurrent Chemoradiation Treatment of Cervical Carcinoma, InÂVitro and InÂVivo. International Journal of Radiation Oncology Biology Physics, 2014, 88, 1180-1187.	0.8	24
12	Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade. Molecular Cancer, 2021, 20, 85.	19.2	23
13	Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas. Leukemia, 2016, 30, 86-93.	7.2	22
14	Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2). Bioorganic and Medicinal Chemistry, 2016, 24, 521-544.	3.0	21
15	A Contaminant Impurity, Not Rigosertib, Is a Tubulin Binding Agent. Molecular Cell, 2020, 79, 180-190.e4.	9.7	14
16	Aberrant expression of JNK-associated leucine-zipper protein, JLP, promotes accelerated growth of ovarian cancer. Oncotarget, 2016, 7, 72845-72859.	1.8	13
17	JNK-associated Leucine Zipper Protein Functions as a Docking Platform for Polo-like Kinase 1 and Regulation of the Associating Transcription Factor Forkhead Box Protein K1. Journal of Biological Chemistry, 2015, 290, 29617-29628.	3.4	9
18	Weighted Gene Co-Expression Network Analysis (WGCNA) Identifies Highly Proliferative Myeloma Subgroup Responsive to CDK4/ARK5 Inhibition. Blood, 2014, 124, 3445-3445.	1.4	9

#	Article	IF	Citations
19	Targeting protein kinase CK2 and CDK4/6 pathways with a multi-kinase inhibitor ON108110 suppresses pro-survival signaling and growth in mantle cell lymphoma and T-acute lymphoblastic leukemia. Oncotarget, 2018, 9, 37753-37765.	1.8	8
20	An In Vivo Functional Screen Identifies miRNA-150 As a Regulator of Hematopoietic Regeneration Post Chemotherapeutic Injury. Blood, 2011, 118, 2333-2333.	1.4	6
21	Evaluation of Rigosertib in Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I/II Study. Blood, 2012, 120, 3794-3794.	1.4	4
22	Rigosertib ameliorates the effects of oncogenic KRAS signaling in a murine model of myeloproliferative neoplasia. Oncotarget, 2019, 10, 1932-1942.	1.8	4
23	Rigosertib Blocks RAS Signaling By Acting As a Small Molecule RAS Mimetic That Binds to the RAS-Binding Domains of RAS Effector Proteins. Blood, 2014, 124, 5616-5616.	1.4	3
24	Rigosertib (RIG) in combination with azacitidine (AZA) to modulate epigenetic effects and to overcome clinical resistance to hypomethylating agents (HMA) in myelodsyplastic syndromes (MDS).. Journal of Clinical Oncology, 2016, 34, 7020-7020.	1.6	3
25	Posiphen Reduces the Levels of Huntingtin Protein through Translation Suppression. Pharmaceutics, 2021, 13, 2109.	4.5	3
26	Evaluation of ON01910.Na In Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I Study. Blood, 2010, 116, 2944-2944.	1.4	2
27	Abstract 1578: Heating it up: Targeting RAS/RAF/PI3K pathway to make melanoma tumors â€˜immunologically hot' and suitable for checkpoint blockade immunotherapies. Cancer Research, 2021, 81, 1578-1578.	0.9	1
28	Predictors Of Response To Rigosertib In Patients With a Myelodysplastic Syndrome (MDS) Or Acute Myeloid Leukemia (AML) Relapsing After Or Refractory To Hypomethylating Agents. Blood, 2013, 122, 1527-1527.	1.4	1
29	Synergistic Effects of a Novel Water-Soluble Small Molecule, ON 013105, and Rituximab on Mantle Cell Lymphoma In Vitro and In Vivo. Blood, 2010, 116, 771-771.	1.4	0
30	Sequential Treatment with Rigosertib Followed By Azacitidine Maximizes the Effects on the Interferon Signaling Pathway in Hematopoietic Cells in Myelodysplastic Syndrome (MDS). Blood, 2018, 132, 5500-5500.	1.4	0
31	The Sequenced Combination of Rigosertib and Azacitidine Has Modulatory Effects on CXCL8, RIG-I like Receptor (RLR) and Wnt/Î²-Catenin Signaling and Downstream Hematopoiesis Pathways in an in Vitro Model of the Myelodysplastic Syndrome. Blood, 2019, 134, 4231-4231.	1.4	0
32	Combination of Ras Modulator and Azacitidine Impacts Innate Immune Signaling Pathway in MDS-L Cell Line. Blood, 2021, 138, 4325-4325.	1.4	0
33	Rigosertib in Combination with Azacitidine Impacts Metabolic and Differentiation Pathways in the MDS-L Cell Line. Blood, 2020, 136, 35-36.	1.4	0